Rivaroxaban Gets NICE Thumbs-Up for DVT

July 26, 2012

July 25, 2012 (London, United Kingdom) — The UK National Institute for Health and Clinical Excellence (NICE) concludes that the oral factor Xa inhibitor rivaroxaban (Xarelto, Bayer) is a cost-effective alternative to warfarin for treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism. It made the statement today [1] on the release of its final guidance document recommending the drug for that indication [2].

The purpose of the NICE document on rivaroxaban, already technically on the market in the UK for the DVT indications, is to establish that it is reimbursable and guide how it is to be reimbursed.

As covered in detail by heartwire , the agency's decision was based largely on positive results from the EINSTEIN-DVT and EINSTEIN-Extension trials--as was the oral factor Xa inhibitor's market approval for DVT by regulators in the European Union in December 2011.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: